IGI Laboratories Announces Approval For Listing On The NASDAQ Global Select Market

BUENA, N.J., Oct. 14, 2015 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey-based specialty generic pharmaceutical company (the "Company"), today announced that it has been approved for listing on the NASDAQ Global Select Market. Trading on the NASDAQ Global Select Market is expected to commence when the market opens on October 26, 2015. The Company's common stock will continue to trade on the NYSE MKT until the market closes on October 23, 2015.

Jason Grenfell-Gardner, President and CEO of the Company, commented, "We are pleased to announce our listing on the NASDAQ Global Select Market. We believe the move to NASDAQ will improve the visibility of our stock, enhance trading liquidity in our shares, and provide us with greater exposure to a broader base of institutional investors."
About IGI Laboratories, Inc.

IGI Laboratories is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market.

For further information: Jenniffer Collins, IGI Laboratories, Inc., (856) 697-1441, www.igilabs.com